Gene Therapy

A team of researchers with the West Virginia School of Medicine are studying how a benign virus can make new treatments for eye diseases possible.

A team of researchers from Thomas Jefferson University have found that immune cells could be doing much more than first thought in protecting our eyes.

The cell-by-cell atlas will help in the study of eye disorders and development of cell therapy to replace damaged eye tissue.

Several research giants will team up to beat rare diseases that are currently using gene therapy.

According to investigators, the virtual reality option could overcome hurdles associated with reliance on a physical course.

Successful treatment options can offer hope for patients with inherited disease.

Investigators believe the therapy could prove to be an option for the treatment of other retinopathies.

PRS can modify disease outcomes due to other genes, such as MYOC.

Investigators from the University of Maryland found that uncovering the mechanism of vision loss in Usher syndrome yields additional drug targets for eventual development of better therapies.

Investigators find that mutations could lead to early treatment intervention.

Improvements are seen after gene therapy for Leber congenital amaurosis.

Investigators have found that the early and late stages of uveal melanoma differ markedly.

According to investigators, aqueous humor analysis differentiated the tumors in patients.

In a study, investigators demonstrated the safety and therapeutic potential of clinically compliant iPSC-derived photoreceptor precursors as a cell replacement source for future clinical trials.

Results from Aurion Biotech's IOTA trial reveals that a corneal endothelial cell therapy showed improvements in visual acuity and central corneal thickness, according to a team of Japanese investigators.

Richard B. Rosen, MD, DSc(Hon), reports on the capabilities of using clinical OCT for imaging and measuring macular surface macrophage cells during the 2021 ASRS annual meeting.

According to 4D Molecular Therapeutics, it has received FDA Clearance of an IND Application for 4D-150, a dual-transgene intravitreal gene therapy for patients with wet AMD.

A team of investigators have found that a molecular mechanism drives the progression of uveal melanoma, an often lethal eye cancer in adults.

AbbVie and REGENXBIO announced a strategic partnership to develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases.

José-Alain Sahel, MD, explains how optogenetics involves artificial photoreceptors from specific retinal cells to restore vision.

The gene-based AAVCOVID vaccine employs a unique adeno-associated viral vector technology that was shown in non-clinical, nonhuman primate studies to enable protection from SARS-CoV-2 challenge and to induce sustained antibody and cellular immune responses from a single dose for up to a year.

Development of new animal model enhances study of potential mutations.

Study examines immunomodulatory therapy as a potential long-term treatment option.

In PIONEER study, investigators outline their successes.

GT005 designed to induce local production of recombinant complement factor I.

CAM’s regenerative healing means long-term relief and fewer visits to clinic.

Cotargeted therapy could help combat inherited retinal diseases.

Clinical trials show subretinal agents are safe, well tolerated by patients.

As soon as 2 weeks after treatment, changes occur to foveal layer.

Investigators uncovered evidence that CaMKII could prove to be a desirable therapeutic target for vision preservation in conditions that damage the axons and somas of retinal ganglion cells.